Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 14

1.

Safety, Tolerability, Pharmacodynamics and Pharmacokinetics of Intravenous Siponimod: A Randomized, Open-label Study in Healthy Subjects.

Shakeri-Nejad K, Gardin A, Gray C, Neelakantham S, Dumitras S, Legangneux E.

Clin Ther. 2020 Jan;42(1):175-195. doi: 10.1016/j.clinthera.2019.11.014. Epub 2020 Jan 8.

2.

Siponimod pharmacokinetics, safety, and tolerability in combination with the potent CYP3A4 inhibitor itraconazole in healthy subjects with different CYP2C9 genotypes.

Gardin A, Shakeri-Nejad K, Feller A, Huth F, Neelakantham S, Dumitras S.

Eur J Clin Pharmacol. 2019 Nov;75(11):1565-1574. doi: 10.1007/s00228-019-02729-7. Epub 2019 Aug 7.

PMID:
31392364
3.

Siponimod pharmacokinetics, safety, and tolerability in combination with rifampin, a CYP2C9/3A4 inducer, in healthy subjects.

Gardin A, Gray C, Neelakantham S, Huth F, Davidson AM, Dumitras S, Legangneux E, Shakeri-Nejad K.

Eur J Clin Pharmacol. 2018 Dec;74(12):1593-1604. doi: 10.1007/s00228-018-2533-2. Epub 2018 Aug 13.

PMID:
30105453
4.

Reduction of a Whole-Body Physiologically Based Pharmacokinetic Model to Stabilise the Bayesian Analysis of Clinical Data.

Wendling T, Tsamandouras N, Dumitras S, Pigeolet E, Ogungbenro K, Aarons L.

AAPS J. 2016 Jan;18(1):196-209. doi: 10.1208/s12248-015-9840-7. Epub 2015 Nov 4.

5.

Application of a Bayesian approach to physiological modelling of mavoglurant population pharmacokinetics.

Wendling T, Dumitras S, Ogungbenro K, Aarons L.

J Pharmacokinet Pharmacodyn. 2015 Dec;42(6):639-57. doi: 10.1007/s10928-015-9430-4. Epub 2015 Aug 1.

PMID:
26231433
6.

Model-based evaluation of the impact of formulation and food intake on the complex oral absorption of mavoglurant in healthy subjects.

Wendling T, Ogungbenro K, Pigeolet E, Dumitras S, Woessner R, Aarons L.

Pharm Res. 2015 May;32(5):1764-78. doi: 10.1007/s11095-014-1574-1. Epub 2014 Nov 26.

PMID:
25425054
7.

Effect of cimetidine, a model drug for inhibition of the organic cation transport (OCT2/MATE1) in the kidney, on the pharmacokinetics of glycopyrronium.

Dumitras S, Sechaud R, Drollmann A, Pal P, Vaidyanathan S, Camenisch G, Kaiser G.

Int J Clin Pharmacol Ther. 2013 Oct;51(10):771-9. doi: 10.5414/CP201946.

PMID:
24040847
8.

The health mediators-qualified interpreters contributing to health care quality among Romanian Roma patients.

Roman G, Gramma R, Enache A, Pârvu A, Moisa ŞM, Dumitraş S, Ioan B.

Med Health Care Philos. 2013 Nov;16(4):843-56. doi: 10.1007/s11019-013-9467-3.

PMID:
23378171
9.

Dying and death in some Roma communities: ethical challenges.

Roman G, Gramma R, Enache A, Pârvu A, Ioan B, Moisa ŞM, Dumitraş S, Chirita R.

J Immigr Minor Health. 2014 Apr;16(2):290-300. doi: 10.1007/s10903-012-9738-8.

PMID:
23097156
10.

Validation of an LC-MS/MS method for the quantitative determination of mavoglurant (AFQ056) in human plasma.

Jakab A, Winter S, Raccuglia M, Picard F, Dumitras S, Woessner R, Mistry S, Chudasama J, Guttikar S, Kretz O.

Anal Bioanal Chem. 2013 Jan;405(1):215-23. doi: 10.1007/s00216-012-6456-y. Epub 2012 Oct 13.

PMID:
23064707
11.

Ethical issues in communication of diagnosis and end-of-life decision-making process in some of the Romanian Roma communities.

Roman G, Enache A, Pârvu A, Gramma R, Moisa ŞM, Dumitraş S, Ioan B.

Med Health Care Philos. 2013 Aug;16(3):483-97. doi: 10.1007/s11019-012-9425-5.

PMID:
22752639
12.

[Detection of fusion gene--integral part of the assessment of children with acute leukemia].

Miron I, Ivanov A, Ivanov I, Dumitraş S.

Rev Med Chir Soc Med Nat Iasi. 2011 Jul-Sep;115(3):731-5. Romanian.

PMID:
22046779
13.
14.

[Statistical study of the evolution over ten years of the clinical and therapeutic approach in childhood soft tissue sarcoma].

Miron I, Miron L, Dumitraş S, Aprodu G, Ciobanu A, Tansanu I.

Rev Med Chir Soc Med Nat Iasi. 2007 Apr-Jun;111(2):358-62. Romanian.

PMID:
17983168

Supplemental Content

Loading ...
Support Center